Baidu
map

Diabetic Med:以网络为基础的1型糖尿病妇女在妊娠和产后早期护理

2018-02-01 MedSci MedSci原创

近日,国际杂志 《Diabetic Med》上在线发表一项关于以人为中心的以网络为基础的1型糖尿病妇女在妊娠和产后早期护理的一项随机对照试验的研究。研究报告一项多中心,平行组,非盲,随机对照试验的结果并探索以在怀孕和产后1型糖尿病妇女基于网络的支持计划的益处和糖尿病管理方面的有效性。 在2011至2014年期间,174名1型糖尿病孕妇被随机分配(1:1 )到网络和标准护理(干预组,n =

近日,国际杂志 《Diabetic Med》上在线发表一项关于以人为中心的以网络为基础的1糖尿病妇女在妊娠和产后早期护理的一项随机对照试验的研究。研究报告一项多中心,平行组,非盲,随机对照试验的结果并探索以在怀孕和产后1糖尿病妇女基于网络的支持计划的益处和糖尿病管理方面的有效性。

20112014年期间,1741型糖尿病孕妇被随机分配(11 )到网络和标准护理(干预组,n = 83)或标准护理(对照组,n = 91)。基于网络护理包括以证据为基础的信息; 监视日常活动的自我照顾日记; 以及在讨论论坛中的同伴支持。主要结果(平均差异,分娩后6个月测量)是幸福感和糖尿病管理

研究表明,经胰岛素给药方法基线差异校正后,总体幸福感的主要结果指标评分[1.0495CI -1.28 to 3.37; P=0.68]和糖尿病管理的自我效能[0.0895CI -0.120.28; P=0.75]没有差异。

研究表明,在分娩后6个月,基于网络和标准护理在糖尿病管理的总体幸福感或自我效能方面并不优于标准护理组。这可能是由于参与人数较少所致。很少有同时积极参与网络计划和糖尿病产后压力是其使用的主要障碍。需要进一步的干预研究从目前的研究中吸取教训。

原始出处:

K. Linden, M. Berg, A. Adolfssonet al. Person-centred, web-based support in pregnancy and early motherhood for women with Type 1 diabetes mellitus: a randomized controlled trial

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1970574, encodeId=2a7619e0574b6, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Sat Jan 12 17:28:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760514, encodeId=18dd1e60514b3, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Oct 02 05:28:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638394, encodeId=588b163839458, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Mar 04 20:28:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608512, encodeId=950616085128b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Feb 03 04:28:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284175, encodeId=2d362841e53a, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Thu Feb 01 14:29:05 CST 2018, time=2018-02-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1970574, encodeId=2a7619e0574b6, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Sat Jan 12 17:28:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760514, encodeId=18dd1e60514b3, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Oct 02 05:28:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638394, encodeId=588b163839458, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Mar 04 20:28:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608512, encodeId=950616085128b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Feb 03 04:28:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284175, encodeId=2d362841e53a, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Thu Feb 01 14:29:05 CST 2018, time=2018-02-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1970574, encodeId=2a7619e0574b6, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Sat Jan 12 17:28:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760514, encodeId=18dd1e60514b3, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Oct 02 05:28:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638394, encodeId=588b163839458, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Mar 04 20:28:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608512, encodeId=950616085128b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Feb 03 04:28:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284175, encodeId=2d362841e53a, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Thu Feb 01 14:29:05 CST 2018, time=2018-02-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1970574, encodeId=2a7619e0574b6, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Sat Jan 12 17:28:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760514, encodeId=18dd1e60514b3, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Oct 02 05:28:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638394, encodeId=588b163839458, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Mar 04 20:28:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608512, encodeId=950616085128b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Feb 03 04:28:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284175, encodeId=2d362841e53a, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Thu Feb 01 14:29:05 CST 2018, time=2018-02-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1970574, encodeId=2a7619e0574b6, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Sat Jan 12 17:28:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760514, encodeId=18dd1e60514b3, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Oct 02 05:28:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638394, encodeId=588b163839458, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Mar 04 20:28:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608512, encodeId=950616085128b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Feb 03 04:28:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284175, encodeId=2d362841e53a, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Thu Feb 01 14:29:05 CST 2018, time=2018-02-01, status=1, ipAttribution=)]
    2018-02-01 sunfeifeiyang

    0

相关资讯

Diabetic Med:对多个种族研究表明男性糖尿病患病率较女性高

近日,国际杂志 《Diabetic Med》上在线发表一项关于来自500 000个英国生物银行参与者的横断面研究结果。研究表明,在一定年龄和BMI的情况下,白人男性患2型糖尿病的比例高于女性,但英国其他族群的等效标准化数据却很少。 这项横断面研究分析了来自英国489 079名参与者的生物银行数据,通过校正了年龄,社会经济状况(SES),BMI和生活方式因素(体力活动,电视观看,水果和蔬菜摄入

J Clin Invest:美科学家在血管研究中发现“逆转糖尿病”的有效新方法!

关于胰岛素如何通过血液代谢细胞中葡萄糖的新见解可能会带来胰岛素抵抗的新治疗,这种情况通常先于2型糖尿病。

美媒:55岁糖尿病患者通过古饮食顺利摆脱糖尿病药物,血糖变正常

流行的古食谱可以帮助糖尿病患者更好地控制血糖。2009年,55岁的史蒂夫被诊断出患有2型糖尿病。

Diabetic Med:HypoAware心理-教育混合干预与1型和胰岛素治疗的2型糖尿病患者的常规护理相比的成本效益如何?

近日,国际杂志 《Diabetic Med》上在线发表一项关于心理-教育混合(团体和在线)HypoAware心理-教育混合干预与1型和胰岛素治疗的2型糖尿病患者的常规护理相比的成本效益如何的分析随机对照试验的研究。为了评估HypoAware的成本效益,这是基于循证血糖意识训练的混合(团体和在线)心理教育干预,与严重低血糖的1型和2型糖尿病患者的常规护理相比,进行成本效益分析。 研究人员使用了

Jama Intern Med:哺乳时间长可减低患糖尿病的风险

近期,JAMA Intern Med杂志上发表一篇文章,提示哺乳持续时间与2型糖尿病的发病率相关。研究人员在美国多个中心进行一以社区为基础的为期30年的前瞻性队列研究,共招募了1238位18-30岁的招募时(1985-1986年)无糖尿病的至少分娩过一次的年轻女性(白种人和黑种人),在随后的30年里(1986-2016年),进行7次糖尿病筛查。总的哺乳持续时间划分为无、0-6个月、6-12个月和1

Diabetic Med:伤口钙卫蛋白和其他炎性生物标志物的水平有助于决定哪些患有糖尿病足溃疡的患者需要抗生素治疗(INDUCE研究)

如果没有经确切的测试,对于确定社区环境中糖尿病足溃疡是否感染仍然是具有一定难度的。近日,国际杂志 《Diabetic Med》上在线发表一项关于伤口钙卫蛋白和其他炎性生物标志物的水平有助于决定哪些患有糖尿病足溃疡的患者需要抗生素治疗(INDUCE研究)的研究。 研究人员研究了用于确定轻度感染的糖尿病足溃疡得四种炎性生物标志物:包括静脉白细胞计数,C-反应蛋白(CRP)和降钙素原以及新型伤口

Baidu
map
Baidu
map
Baidu
map